PDE4 is a key inflammatory mediator
- PDE4 is active in immune cells, keratinocytes, and synovial cells
- PDE4 converts cAMP to AMP, which increases inflammatory signaling
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
Targeting key intracellular signals to reduce inflammation2
PDE4 is a key inflammatory mediator
OTEZLA is an oral PDE4 inhibitor
Blocking PDE4 helps regulate immune signaling
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.